申请人:Schering Aktiengesellschaft
公开号:US04269847A1
公开(公告)日:1981-05-26
Imidazole derivatives of the formula ##STR1## wherein Ar.sub.1 and Ar.sub.2 are each phenyl; phenyl substituted by halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or C.sub.2-6 dialkylamino; pyridyl; furyl; or thienyl; with the proviso that Ar.sub.1 and Ar.sub.2 are not both unsubstituted phenyl; R.sub.1 is hydrogen, C.sub.1-4 alkyl or C.sub.1-4 alkyl substituted by hydroxy, C.sub.1-4 alkoxy or C.sub.1-6 alkanoyloxy; n is 0, 1 or 2; and Z is a C.sub.2-6 -alkyl or -alkenyl residue substituted by one or two of hydroxy, C.sub.1-4 alkoxy, C.sub.2-8 alkylenedioxy, C.sub.1-6 alkanoyloxy or benzoyloxy, or by one alkoxycarbonyl group; and the salts thereof with physiologically acceptable acids, possess valuable pharmacological properties.
咪唑衍生物的化学式为##STR1##其中Ar.sub.1和Ar.sub.2均为苯基;苯基被卤素、C.sub.1-4烷基、C.sub.1-4烷氧基或C.sub.2-6二烷基氨基取代;吡啶基;呋喃基;或噻吩基;但Ar.sub.1和Ar.sub.2不能都是未取代的苯基;R.sub.1为氢、C.sub.1-4烷基或C.sub.1-4烷基被羟基、C.sub.1-4烷氧基或C.sub.1-6烷酰氧基取代;n为0、1或2;Z为C.sub.2-6-烷基或-烯基残基,被一个或两个羟基、C.sub.1-4烷氧基、C.sub.2-8烷二氧基、C.sub.1-6烷酰氧基或苯甲酰氧基取代,或者被一个烷氧羰基基团取代;以及其与生理上可接受的酸形成的盐具有有价值的药理学性质。